Assessment of the effect of DMARD use on the mortality of patients with rheumatoid arthritis Romatoid artrit hastalarında DMARD kullanımının mortalite üzerine etkisinin araştırılması
Journal of Turkish Society For Rheumatology, cilt.14, sa.2, ss.58-65, 2022 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 14 Sayı: 2
- Basım Tarihi: 2022
- Doi Numarası: 10.4274/raed.galenos.2022.54264
- Dergi Adı: Journal of Turkish Society For Rheumatology
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.58-65
- Anahtar Kelimeler: antirheumatic agents, mortality, Rheumatoid arthritis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: The aim of this study was to investigate the causes of mortality in patients diagnosed with rheumatoid arthritis (RA) and the effects of disease-modifying antirheumatic drugs (DMARDs) to be used for treating RA on mortality. Methods: A total of 743 patients with RA over the age of 18 who attended between 2010 and 2020 in the hospital where this study was conducted, were included in the study. The patients’ clinical and laboratory information were obtained from the hospital database, whereas the relevant mortality and population data were obtained from the Turkish Ministry of Health system and the Turkish Statistical Institute, respectively. The standardized mortality ratio (SMR) was calculated by dividing the number of mortality observed in the cohort by the number of mortality in the Turkish population of the same age and gender. Patients were divided into two groups: Those who used only conventional (cDMARDs) and those who took cDMARDs plus biological (bDMARDs). Results: Mortality occurred in 61 patients from the 743 patients with RA. SMR of the patients with RA was found to be 1.42 [confidence interval (CI) 1.09-1.81)] in the Turkish population. SMR was determined to be higher in the cDMARD cohort than in the bDMARD cohort [2.05 (CI 1.53-2.69) and 0.66 (CI 0.37-1.11), respectively]. The most common causes of mortality in patients with RA were determined as cardiovascular diseases 18 (29.5%), infectious diseases 13 (21.3%) and respiratory system diseases 12 (19.7%). Conclusion: This study is the first mortality study reported from Turkey in patients with a diagnosis of RA. Generally, there is an increased mortality in patients with RA compared with the Turkish population. Therefore, to reduce mortality in patients with RA, patients with RA should be followed more carefully, and treated more effectively in terms of both RA and any comorbid diseases they might have.